EMEA recomiendan retiro de RAPTIVA (Genentech Inc)

European regulators recommended suspending sales of Genentech Inc.’s psoriasis treatment Raptiva after the drug was linked to as many as two additional cases of a deadly brain infection.

The U.S. Food and Drug Administration and European Medicines Agency have received reports of three confirmed cases and one possible case of progressive multifocal leukoencephalopathy, or PML, in patients taking Raptiva, the agencies said today. Three of the patients died. The South San Francisco-based company reported its second patient death from the infection in November.

Mas...


Mas...